CBAY Key Statistics, Chart & Performance
The current stock price of CBAY is 32.48 USD. In the past month the price increased by 0.96%. In the past year, price increased by 283.47%.
CBAY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CBAY. When comparing the yearly performance of all stocks, CBAY is one of the better performing stocks in the market, outperforming 98.73% of all stocks.
CBAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CBAY. The financial health of CBAY is average, but there are quite some concerns on its profitability.
CBAY Financial Highlights
Over the last trailing twelve months CBAY reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 19.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.24% | ||
| ROE | -36.05% | ||
| Debt/Equity | 0.34 |
CBAY Forecast & Estimates
16 analysts have analysed CBAY and the average price target is 33.15 USD. This implies a price increase of 2.06% is expected in the next year compared to the current price of 32.48.
For the next year, analysts expect an EPS growth of -50.27% and a revenue growth -62.23% for CBAY
CBAY Ownership
CBAY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CBAY
Company Profile
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California and currently employs 60 full-time employees. The company went IPO on 2014-01-16. The firm is focused on developing therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
Company Info
CYMABAY THERAPEUTICS INC
Suite 130, 7999 Gateway Blvd
Newark California CALIFORNIA 94560 US
CEO: Sujal Shah
Employees: 60
Phone: 15102938800
CYMABAY THERAPEUTICS INC / CBAY FAQ
What does CBAY do?
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California and currently employs 60 full-time employees. The company went IPO on 2014-01-16. The firm is focused on developing therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
Can you provide the latest stock price for CYMABAY THERAPEUTICS INC?
The current stock price of CBAY is 32.48 USD. The price increased by 0.03% in the last trading session.
Does CBAY stock pay dividends?
CBAY does not pay a dividend.
What is the ChartMill rating of CYMABAY THERAPEUTICS INC stock?
CBAY has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CBAY stock?
16 analysts have analysed CBAY and the average price target is 33.15 USD. This implies a price increase of 2.06% is expected in the next year compared to the current price of 32.48.
What is CYMABAY THERAPEUTICS INC worth?
CYMABAY THERAPEUTICS INC (CBAY) has a market capitalization of 3.73B USD. This makes CBAY a Mid Cap stock.